Platelet Refractoriness After Multiple Transfusions
A 52-year-old man with myelodysplastic syndrome has received 14 platelet transfusions over 6 months, now roughly twice weekly. His pre-transfusion platelet count is 8 × 10^9/L; a 1-hour post-transfusion count is 12 × 10^9/L, and a 24-hour count is 6 × 10^9/L. He has no fever, no splenomegaly, no bleeding, and is not on amphotericin or vancomycin. His ABO is O positive. He has no HLA antibodies documented yet. The blood bank has both random-donor pooled platelets and a limited supply of HLA-matched apheresis platelets. His clinician asks whether to switch products and what workup is warranted.
1. Calculate the corrected count increment (CCI) and interpret whether this represents immune or non-immune refractoriness.
Read the worked answer
CCI = (post − pre count in ×10^9/L) × body surface area (m²) ÷ (platelets transfused × 10^11) × 10^9/L.
Using a typical adult BSA of ~1.8 m² and a standard apheresis dose of ~3.0 × 10^11 platelets:
- 1-hour: (12 − 8) = 4 × 10^9/L × 1.8 ÷ 3.0 = 2.4 (×10^9/L per 10^11).
- 24-hour: (6 − 8) is negative, so CCI is effectively 0.
Interpretation: A 1-hour CCI < 5,000-7,500 (depending on units) and 24-hour CCI < 4,500-5,000 indicates refractoriness. Both values are far below threshold. The 1-hour CCI is already low, which points to immune-mediated destruction (HLA or HPA antibodies) rather than purely non-immune causes, since non-immune causes (sepsis, splenomegaly, DIC, drugs) typically lower the 24-hour more than the 1-hour. However, the 1-hour value alone does not exclude non-immune causes, so the workup should proceed.
Next steps: Send HLA antibody screen (and HPA if HLA-negative), review medications, and evaluate for splenomegaly/sepsis. The pattern strongly suggests immune refractoriness requiring matched or crossmatched platelets.
2. What product should be selected while HLA antibody testing is pending, and what is the rationale for each option?
Read the worked answer
While awaiting HLA antibody results:
- HLA-matched apheresis platelets - best option if a match can be found; requires HLA typing of the patient and donor selection. Limited supply means reserve for the most refractory patients.
- HLA-selected (antigen-negative) platelets - if the patient's HLA antibody specificities are known, select donors lacking those antigens.
- Platelet crossmatch-compatible platelets - a practical bridge when HLA antibodies are unknown; crossmatch-negative units often give adequate increments.
- ABO-identical units are preferred; ABO-nonidentical platelets can reduce increments modestly but are acceptable if supply is limited.
Avoid: continuing random-donor pooled platelets at the current frequency - they are unlikely to produce increments and waste product.
Also: Confirm the patient is not bleeding and consider whether prophylactic transfusion is needed at all; if the count is 8 × 10^9/L without bleeding, some patients can be managed with a higher threshold or observed, but this patient's very low count warrants support. Document the refractoriness and coordinate with the HLA laboratory.